# Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development (93.360)

Source: https://welltoldgrants.com/programs/93-360-biomedical-advanced-research-and-development-authority/  
Publisher: Well Told Grants. Data: USAspending.gov and Grants.gov, updated November 7, 2026.

Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development is run by Department of Health and Human Services. From fiscal 2021 to 2025 it awarded $1.4 billion in 211 grants, about $6.7 million per award.

## Objectives

The purpose of this program is to coordinate the acceleration of countermeasure and product advanced research and development by—(A) facilitating collaboration between the Department of Health and Human Services and other Federal agencies, relevant industries, academia, and other persons, with respect to such advanced research and development; (B) promoting countermeasure and product advanced research and development; (C) facilitating contacts between interested persons and the offices or employees authorized by the Secretary to advise such persons regarding requirements under the Federal Food, Drug, and Cosmetic Act and under section 351 of the Public Health Service Act; and (D) promoting innovation to reduce the time and cost of countermeasure and product advanced research and development. The Public Health Service Act at 42 U.S.C. 247d-6a defines a qualified countermeasure as “…a drug (as that term is defined by section 321(g)(1) of title 21), biological product (as that term is defined by section 262(i) of this title), or device (as that term is defined by section 321(h) of title 21), that the Secretary determines to be a priority (consistent with sections 182(2) and 184(a) of title 6) to - (i) diagnose, mitigate, prevent, or treat harm from any biological agent (including organisms that cause an infectious disease) or toxin, chemical, radiological, or nuclear agent that may cause a public health emergency affecting national security; or (ii) diagnose, mitigate, prevent, or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug, biological product, or device that is used as described in this subparagraph”

## Funding by fiscal year

| Year | Amount | Awards |
|---|---|---|
| 2021 | $29.7 million | 25 |
| 2022 | $174 million | 164 |
| 2023 | $1.3 billion | 78 |
| 2024 | -$116 million | 4 |
| 2025 | -$6.3 million | 0 |

## Largest recipients

| Recipient | State | Amount |
|---|---|---|
| Global Life Sciences Solutions USA LLC | Massachusetts | $271 million |
| Evonik Corporation | New Jersey | $145 million |
| Jubilant Hollisterstier LLC | Washington | $115 million |
| Curia New Mexico LLC | New Mexico | $106 million |
| Corning Incorporated | New York | $88.8 million |
| Grand River Aseptic Manufacturing, Inc. | Michigan | $82.2 million |
| Croda Inc | New Jersey | $64.7 million |
| Ompi of America Inc | Pennsylvania | $61.3 million |
| Duke University | North Carolina | $54.9 million |
| Gerresheimer Glass Inc | New Jersey | $47.2 million |
| Emory University | Georgia | $40.9 million |
| Schott Pharma USA, Inc. | Pennsylvania | $38.0 million |
| Exela Pharma Sciences LLC | North Carolina | $28.3 million |
| Endo USA, Inc. | Pennsylvania | $20.6 million |
| Trustees of Boston University | Massachusetts | $19.4 million |
| Par Sterile Products, LLC | Michigan | $17.3 million |
| The Johns Hopkins University | Maryland | $13.5 million |
| Yale Univ | Connecticut | $13.3 million |
| Trilink Biotechnologies, LLC | California | $12.7 million |
| University of California, San Diego | California | $10.4 million |